Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 4/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | CES1 | P23141 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21470081 | 0.87 | GSK3B (0.57) | GSK3BALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL31274029 | 0.85 | GSK3B (0.55) | GSK3BALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL17148448 | 0.84 | KMT2A (0.52) | ALDH1A1KMT2AMAPTLMNARAB9A | |
| SCHEMBL11832775 | 0.83 | GSK3B (0.53) | GSK3BALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL30340784 | 0.83 | GSK3B (0.53) | GSK3BALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL14289820 | 0.83 | GSK3B (0.53) | GSK3BALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL6781250 | 0.83 | HSD17B3 (0.55) | ALDH1A1NPC1RAB9APOLBKDM4E | |
| SCHEMBL11900206 | 0.83 | TDP1 (0.53) | ALDH1A1KMT2AMAPTLMNAPOLB | |
| SCHEMBL8775647 | 0.82 | ALDH1A1 (0.58) | GSK3BALDH1A1KMT2AMAPTLMNA | |
| SCHEMBL5797936 | 0.81 | TDP1 (0.51) | ALDH1A1KMT2AMAPTLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11744825-B2 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds | AFASCI, INC. (US) | 2023-09-05 | — | — | US | disclosed |
| US-20220193080-A1 | ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR | UNIVERSITY OF THE SCIENCES (US) | 2022-06-23 | — | — | US | disclosed |
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | THE TRUSTEES OF PRINCETON UNIVERSITY | 2020-05-14 | — | — | US | disclosed |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | OCEAN UNIVERSITY OF CHINA (CN) | 2020-01-30 | — | — | US | disclosed |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2020-01-21 | — | — | US | disclosed |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-05-17 | — | — | US | disclosed |
| US-9901572-B2 | Aryl dihydropyridinones and piperidinone MGAT2 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-02-27 | — | — | US | disclosed |
| US-9856246-B2 | TRPM8 antagonists | DOMPÉ FARMACEUTICI S.P.A. (IT) | 2018-01-02 | — | — | US | disclosed |
| US-9770026-B2 | Substituted pyrimidine compound and uses thereof | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2017-09-26 | — | — | US | disclosed |
| US-20170216263-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2017-08-03 | — | — | US | disclosed |
| US-20080280903-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-13 | — | — | US | disclosed |
| US-20080280903-A1 | Apoptosis Inhibitors | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2008-11-13 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | ELI LILLY AND COMPANY | 2008-10-30 | — | — | US | disclosed |
| EP-1924561-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | Eli Lilly & Company (US) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| WO-2007028083-A2 | 6-ARYLALKYLAMINO- 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2007-03-08 | — | — | WO | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11744825-B2 | Methods of treating hypersensitive cough or itching using ion channel inhibitory compounds | TRPV1, TRPA1, TRPV2 | GSK3B 3852/4885ALDH1A1 3199/4885KMT2A 3305/4885 |
| US-20180133198-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | GSK3B 2605/4885ALDH1A1 284/4885KMT2A 155/4885 |
| US-20200030312-A1 | Lactam Compound, Preparation Method and Use thereof | FURIN, PEPD, PIN1 | GSK3B 21/4885ALDH1A1 4014/4885KMT2A 3643/4885 |
| US-20080280903-A1 | Apoptosis Inhibitors | BAD, MCL1, AIFM1 | GSK3B 584/4885ALDH1A1 2244/4885KMT2A 4027/4885 |
| US-10538509-B2 | Decarboxylative cross-coupling and applications thereof | PPOX, DDC, DDO | GSK3B 4241/4885ALDH1A1 130/4885KMT2A 1237/4885 |
| US-20170216263-A1 | ARYL DIHYDROPYRIDINONES AND PIPERIDINONE MGAT2 INHIBITORS | DGAT2, MGAT2, MGAT1 | GSK3B 2605/4885ALDH1A1 284/4885KMT2A 155/4885 |
| US-20080269196-A1 | 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists | HTR2C, HTR1A, HTR2A | GSK3B 3471/4885ALDH1A1 397/4885KMT2A 1221/4885 |
| US-20220193080-A1 | ALLOSTERIC AGONISTS AND POSITIVE ALLOSTERIC MODULATORS OF GLUCAGON-LIKE PEPTIDE 1 RECEPTOR | GLP1R, GPR119, GIPR | GSK3B 1379/4885ALDH1A1 4778/4885KMT2A 2312/4885 |
| US-20200148668-A1 | DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF | PPOX, DDO, DDC | GSK3B 4405/4885ALDH1A1 149/4885KMT2A 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.